All Updates

All Updates

icon
Filter
Partnerships
XyloCor Therapeutics and SmartWise partner to advance gene therapies for cardiovascular disease
Cell & Gene Therapy
Jul 10, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
Cell & Gene Therapy

Cell & Gene Therapy

Jul 10, 2024

XyloCor Therapeutics and SmartWise partner to advance gene therapies for cardiovascular disease

Partnerships

  • XyloCor Therapeutics has entered into a licensing agreement with SmartWise, a subsidiary of SmartCella Holding AB, giving XyloCor access to SmartWise's proprietary Extroducer Infusion Catheter System for cardiovascular treatment. The total deal value and mid-single-digit royalties are approximately USD 130 million.

  • The agreement will allow the use of the Extroducer novel endovascular device to deliver XyloCor’s top gene therapy candidate, XC001, directly to the heart less invasively, reducing possible surgical complications. The therapy aims to decrease the ischemic load by creating new blood vessels to improve blood flow in heart patients suffering from refractory angina.

  • XyloCor Therapeutics is a biopharmaceutical company specializing in gene therapy for cardiovascular disease, particularly advanced coronary artery disease. Its lead product candidate, XC001 (encoberminogene rezmadenovec), is a single-dose gene therapy currently in clinical development for treating refractory angina, which is a condition characterized by chronic chest pain due to insufficient blood flow to the heart. XyloCor also has a preclinical candidate, XC002, who treats heart attack-related cardiac tissue damage​.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.